All Trials

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with measurable first-line ES-SCLC, either treatment-naïve or without progression after 3–4 cycles of platinum/etoposide plus anti–PD-1/PD-L1 therapy. Regimens test gocatamig/MK-6070, a DLL3/CD3 trispecific T-cell engager, plus ifinatamab deruxtecan/MK-2400, a B7-H3–directed topoisomerase I ADC, as maintenance and/or induction-maintenance therapy, with a standard carboplatin/etoposide/atezolizumab comparator in untreated patients.

ClinicalTrials.gov ID: NCT07227597

A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Enrolling adults with unresectable or metastatic, measurable GIST in the first-line advanced-disease setting, with imatinib-sensitive KIT mutations excluding exon 9 or PDGFRA mutations excluding D842V. All patients receive oral KQB198, an investigational SOS1/RAS pathway inhibitor, in combination with standard imatinib, a KIT/PDGFRA tyrosine kinase inhibitor.

ClinicalTrials.gov ID: NCT07406633

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent IDH-wildtype glioblastoma, KPS >60, and disease amenable to serial biopsy or resection receive IV LMP744 for 5 consecutive days every 28 days for up to 12 cycles. LMP744 is an indenoisoquinoline topoisomerase I poison that causes persistent DNA damage and may suppress MYC; matched tumor biopsies are obtained before and after initial exposure.

ClinicalTrials.gov ID: NCT07416188

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with previously untreated locally advanced or metastatic HR-positive/HER2-negative breast cancer and ECOG 0–1 receive letrozole plus either investigational BGB-43395, a selective CDK4 inhibitor that suppresses RB1 phosphorylation, or investigator-selected abemaciclib, palbociclib, or ribociclib.

ClinicalTrials.gov ID: NCT07492641

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults aged 18–75 with measurable locally advanced or metastatic protocol-specified epithelial solid tumors, ECOG 0–1, and applicable molecular testing are eligible. Treatment is IV AVZO-1418, an EGFR/HER3-targeted bispecific antibody–drug conjugate delivering a topoisomerase I inhibitor payload, as monotherapy with potential protocol-defined combination cohorts.

ClinicalTrials.gov ID: NCT07038343

A Pilot Study of Botensilimab and Balstilimab and SBRT in Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with chemorefractory or treatment-intolerant MSS/pMMR colorectal adenocarcinoma, 1–5 liver metastases amenable to ablative SBRT, and measurable unirradiated extrahepatic disease receive liver-directed SBRT plus botensilimab, an Fc-enhanced anti-CTLA-4 antibody, and balstilimab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT07128355

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring specified RAS mutations, ECOG 0–1, generally without acceptable standard systemic options; a newly diagnosed pancreatic ductal adenocarcinoma cohort is also eligible. Patients receive oral ERAS-0015, a pan-RAS molecular glue that disrupts active RAS–effector interactions and inhibits MAPK signaling, alone or with other investigational anticancer agents.

ClinicalTrials.gov ID: NCT06983743

A Phase Ib/II Study of Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Hepatocellular Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, noncurable advanced hepatocellular carcinoma, ECOG 0–1, and Child-Pugh A or selected B7–B8 cirrhosis after progression on or intolerance to 1–2 prior systemic therapies receive oral zanzalintinib once daily. Zanzalintinib is a multitarget tyrosine kinase inhibitor of VEGFR2, MET, and TYRO3/AXL/MER.

ClinicalTrials.gov ID: NCT07042919

A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive metastatic castration-resistant prostate adenocarcinoma after at least one androgen receptor pathway inhibitor and exactly one taxane regimen receive xaluritamig monotherapy with ongoing medical castration. Xaluritamig is a bispecific T-cell engager targeting STEAP1 on prostate cancer cells and CD3 on T cells to promote tumor-cell killing.

ClinicalTrials.gov ID: NCT07493512

A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive PSMA-positive metastatic castration-resistant prostate adenocarcinoma after one prior novel androgen receptor pathway inhibitor receive AZD9574, a selective PARP1 inhibitor, plus AZD2265, an actinium-225 PSMA-targeted alpha radioligand. Expansion cohorts compare the combination with AZD2265 monotherapy and docetaxel.

ClinicalTrials.gov ID: NCT07590934